These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 23011856

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.
    Negro A, Curto M, Lionetto L, Martelletti P.
    J Headache Pain; 2015; 17():1. PubMed ID: 26792662
    [Abstract] [Full Text] [Related]

  • 3. Botulinum toxin type A and acute drug costs in migraine with triptan overuse.
    Christie SN, Giammarco R, Gawel M, Mackie G, Gladstone J, Becker WJ.
    Can J Neurol Sci; 2010 Sep; 37(5):588-94. PubMed ID: 21059503
    [Abstract] [Full Text] [Related]

  • 4. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK, Sadowsky CH, Martinez WC, Zuniga JA, Poulette A.
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Impulse control disorders in chronic migraine with medication overuse after onabotulinumtoxinA: A single-center prospective cohort study.
    d'Onofrio F, de Falco A, Costanzo A, Spitaleri D, Casucci G, Raimo S.
    J Clin Neurosci; 2020 Oct; 80():152-155. PubMed ID: 33099338
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Clinical experience of treatment with onabotulinumtoxin A in patients with refractory migraine].
    Palma JA, Irimia P, Fernandez-Torron R, Ortega-Cubero S, Riverol M, Luquin MR, Martinez-Vila E.
    Rev Neurol; 2012 Jun 16; 54(12):705-11. PubMed ID: 22673946
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW.
    J Neurol Sci; 2013 Aug 15; 331(1-2):48-56. PubMed ID: 23790235
    [Abstract] [Full Text] [Related]

  • 11. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders.
    Blumenfeld A.
    Headache; 2003 Sep 15; 43(8):853-60. PubMed ID: 12940806
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Botulinum toxin type A for migraine prophylaxis in the Japanese population: an open-label prospective trial.
    Suzuki K, Iizuka T, Sakai F.
    Intern Med; 2007 Sep 15; 46(13):959-63. PubMed ID: 17603233
    [Abstract] [Full Text] [Related]

  • 15. [Predictive factors of the response to treatment with onabotulinumtoxinA in refractory migraine].
    Pagola I, Esteve-Belloch P, Palma JA, Luquin MR, Riverol M, Martinez-Vila E, Irimia P.
    Rev Neurol; 2014 Mar 16; 58(6):241-6. PubMed ID: 24610690
    [Abstract] [Full Text] [Related]

  • 16. Chronic migraine: current concepts and ongoing treatments.
    Negro A, Rocchietti-March M, Fiorillo M, Martelletti P.
    Eur Rev Med Pharmacol Sci; 2011 Dec 16; 15(12):1401-20. PubMed ID: 22288302
    [Abstract] [Full Text] [Related]

  • 17. The use of onabotulinum toxin A (Botox(®)) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study.
    Russo M, Manzoni GC, Taga A, Genovese A, Veronesi L, Pasquarella C, Sansebastiano GE, Torelli P.
    Neurol Sci; 2016 Jul 16; 37(7):1127-31. PubMed ID: 27048312
    [Abstract] [Full Text] [Related]

  • 18. [Management of chronic daily headache in migraine patients: medication overuse headache and chronic migraine. French guidelines (French Headache Society, French Private Neurologists Association, French Pain Society)].
    Lantéri-Minet M, Demarquay G, Alchaar H, Bonnin J, Cornet P, Douay X, Dousset V, Géraud G, Guillouf V, Navez M, Radat F, Radenne S, Revol A, Valade D, Donnet A.
    Rev Neurol (Paris); 2014 Mar 16; 170(3):162-76. PubMed ID: 24594364
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Refractory chronic migraine: is drug withdrawal necessary before starting a therapy with onabotulinum toxin type A?
    Butera C, Colombo B, Bianchi F, Cursi M, Messina R, Amadio S, Guerriero R, Comi G, Del Carro U.
    Neurol Sci; 2016 Oct 16; 37(10):1701-6. PubMed ID: 27395386
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.